Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.67 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 3/20 | 0.42 |
| ▸ | VCP | P55072 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2951205 | 0.88 | HRH3 (0.67) | HRH3ROCK2CYP3A4MEN1KMT2A | |
| SCHEMBL2950114 | 0.86 | HRH3 (0.73) | HRH3ROCK2CYP3A4MEN1KMT2A | |
| SCHEMBL3844454 | 0.83 | HRH3 (0.56) | HRH3ROCK2CYP3A4VCP | |
| SCHEMBL2952603 | 0.82 | HRH3 (0.83) | HRH3MEN1KMT2ASYK | |
| SCHEMBL2951314 | 0.82 | HRH3 (0.64) | HRH3ROCK2CYP3A4MEN1KMT2A | |
| SCHEMBL2947010 | 0.82 | HRH3 (0.82) | HRH3MEN1KMT2ASYK | |
| SCHEMBL2943709 | 0.81 | HRH3 (0.66) | HRH3MEN1KMT2A | |
| SCHEMBL2952637 | 0.81 | HRH3 (0.66) | HRH3ROCK2CYP3A4MEN1KMT2A | |
| SCHEMBL1379104 | 0.80 | HRH3 (0.68) | HRH3 | |
| SCHEMBL2947472 | 0.80 | HRH3 (1.00) | HRH3SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1841734-B1 | 5-AMINOINDOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-07-29 | — | — | EP | claimed |
| US-20090069311-A1 | 5-AMINOINDOLE DERIVATIVES AS H3 INVERSE AGONISTS | NETTEKOVEN MATTHIAS HEINRICH | 2009-03-12 | — | — | US | claimed |
| EP-1841734-A2 | 5-AMINOINDOLE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-10-10 | — | — | EP | claimed |
| WO-2006077024-A2 | 5-AMINOINDOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-27 | — | — | WO | claimed |
| US-20060160855-A1 | 5-Aminoindole derivatives as H3 inverse agonists | HOFFMANN-LA ROCHE INC. | 2006-07-20 | — | — | US | claimed |
| US-7754736-B2 | 5-aminoindole derivatives as H3 inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2010-07-13 | — | — | US | disclosed |
| EP-1841734-B1 | 5-AMINOINDOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-07-29 | — | — | EP | disclosed |
| US-20090069311-A1 | 5-AMINOINDOLE DERIVATIVES AS H3 INVERSE AGONISTS | NETTEKOVEN MATTHIAS HEINRICH | 2009-03-12 | — | — | US | disclosed |
| US-7456174-B2 | 5-aminoindole derivatives as H3 inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1841734-A2 | 5-AMINOINDOLE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006077024-A2 | 5-AMINOINDOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-27 | — | — | WO | disclosed |
| US-20060160855-A1 | 5-Aminoindole derivatives as H3 inverse agonists | HOFFMANN-LA ROCHE INC. | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069311-A1 | 5-AMINOINDOLE DERIVATIVES AS H3 INVERSE AGONISTS | HRH3, HTR5A, HRH4 | HRH3 1/4885ROCK2 1560/4885CYP3A4 824/4885 |
| US-20060160855-A1 | 5-Aminoindole derivatives as H3 inverse agonists | HRH3, HTR5A, HRH4 | HRH3 1/4885ROCK2 1560/4885CYP3A4 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.